These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33541393)

  • 1. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.
    Mori Y; Izumiyama T; Kurishima H; Kamimura M; Baba K; Mori N; Itoi E
    J Orthop Surg Res; 2021 Feb; 16(1):107. PubMed ID: 33541393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
    Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
    Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.
    Hu Q; Zhong X; Tian H; Liao P
    Front Immunol; 2021; 12():799575. PubMed ID: 35069583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
    Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
    Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
    Mochizuki T; Yano K; Ikari K; Kawakami K; Hiroshima R; Koenuma N; Ishibashi M; Momohara S
    J Bone Miner Metab; 2018 Jul; 36(4):431-438. PubMed ID: 28681148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparable efficacy of denosumab on bone mineral density in rheumatoid arthritis patients with postmenopausal osteoporosis: A retrospective case-control study.
    Kim SK; Kim JW; Lee H; Park SH; Choe JY; Kim B
    Medicine (Baltimore); 2023 Jun; 102(26):e34219. PubMed ID: 37390268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
    J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
    Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
    Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
    Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
    Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
    Tanaka Y; Takeuchi T; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    J Rheumatol; 2021 Nov; 48(11):1663-1671. PubMed ID: 33858976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
    Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
    BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
    Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.